Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 9/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7717397 | 1.00 | IDO1 (0.47) | IDO1KCNH2CYP11B2CYP11B1HTT | |
| SCHEMBL7161656 | 1.00 | IDO1 (0.47) | IDO1KCNH2CYP11B2CYP11B1HTT | |
| SCHEMBL21390948 | 0.78 | CYP11B2 (0.59) | CYP11B2CYP11B1HTTADRB1ADRA2A | |
| SCHEMBL12076604 | 0.69 | SMN1; SMN2 (0.54) | IDO1KCNH2CYP11B2CYP11B1HTT | |
| SCHEMBL13543527 | 0.68 | SMN1; SMN2 (0.53) | KCNH2CYP11B2CYP11B1HTTSMN1; SMN2 | |
| SCHEMBL3523976 | 0.68 | SMN1; SMN2 (0.53) | KCNH2CYP11B2CYP11B1HTTSMN1; SMN2 | |
| SCHEMBL21390931 | 0.67 | ALDH1A1 (0.62) | KCNH2CYP11B2CYP11B1HTTSMN1; SMN2 | |
| SCHEMBL1014610 | 0.67 | SMN1; SMN2 (0.58) | KCNH2CYP11B2CYP11B1HTTSMN1; SMN2 | |
| SCHEMBL1014609 | 0.67 | SMN1; SMN2 (0.58) | KCNH2CYP11B2CYP11B1HTTSMN1; SMN2 | |
| SCHEMBL17678354 | 0.65 | CYP11B2 (0.58) | CYP11B2CYP11B1ADRB1ADRA2ACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116443-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC | 2004-06-17 | — | — | US | claimed |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2003-08-21 | — | — | US | claimed |
| US-20020049209-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2002-04-25 | — | — | US | claimed |
| EP-1177792-A2 | Dopamine D4 Ligands for the treatment of novelty-seeking disorders | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | claimed |
| EP-0953567-A2 | Bicyclic substituted piperazine-, piperidine- and tetrahydropyridine derivatives, their preparation and their use as agents with central dopaminergic (dopamine D4 receptor) activity | Pfizer Products Inc. (US) | 1999-11-03 | — | — | EP | claimed |
| US-20040116443-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC | 2004-06-17 | — | — | US | disclosed |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2003-08-21 | — | — | US | disclosed |
| US-6372762-B1 | HETEROCYCLIC COMPOUNDS FOR NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-04-16 | — | — | US | disclosed |
| EP-1177792-A2 | Dopamine D4 Ligands for the treatment of novelty-seeking disorders | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
| EP-0953567-A2 | Bicyclic substituted piperazine-, piperidine- and tetrahydropyridine derivatives, their preparation and their use as agents with central dopaminergic (dopamine D4 receptor) activity | Pfizer Products Inc. (US) | 1999-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049209-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | SLC6A3, DRD4, DRD2 | IDO1 1874/4885KCNH2 2094/4885CYP11B2 3947/4885 |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | SLC6A3, DRD4, DRD2 | IDO1 1874/4885KCNH2 2094/4885CYP11B2 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.